{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:17:23Z","timestamp":1792095443027,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00520-021-06437-w","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T04:02:31Z","timestamp":1629086551000},"page":"8097-8107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["MASCC antiemetics in advanced cancer updated guideline"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-3993","authenticated-orcid":false,"given":"Mellar","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"DeFeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Del Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"2","key":"6437_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-020-0704-8","volume":"21","author":"RM Navari","year":"2020","unstructured":"Navari RM (2020) Nausea and vomiting in advanced cancer. Curr Treat Options in Oncol 21(2):14","journal-title":"Curr Treat Options in Oncol"},{"issue":"4","key":"6437_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jpainsymman.2009.08.010","volume":"39","author":"MP Davis","year":"2010","unstructured":"Davis MP, Hallerberg G (2010) Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and\/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag 39(4):756\u2013767","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"6437_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","volume":"25","author":"D Walsh","year":"2017","unstructured":"Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A (2017) 2016 Updated MASCC\/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer 25(1):333\u2013340","journal-title":"Support Care Cancer"},{"issue":"4","key":"6437_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jpainsymman.2004.01.009","volume":"28","author":"E Bruera","year":"2004","unstructured":"Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, Willey J, Strasser F, Palmer JL (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag 28(4):381\u2013388","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"6437_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0885-3924(00)00138-X","volume":"19","author":"E Bruera","year":"2000","unstructured":"Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A (2000) A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manag 19(6):427\u2013435","journal-title":"J Pain Symptom Manag"},{"issue":"12","key":"6437_CR6","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1002\/1097-0142(19941215)74:12<3204::AID-CNCR2820741220>3.0.CO;2-G","volume":"74","author":"ED Bruera","year":"1994","unstructured":"Bruera ED, MacEachern TJ, Spachynski KA et al (1994) Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer. 74(12):3204\u20133211","journal-title":"Cancer."},{"issue":"7","key":"6437_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0885-3924(95)00105-8","volume":"10","author":"O Corli","year":"1995","unstructured":"Corli O, Cozzolino A, Battaiotto L (1995) Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. J Pain Symptom Manag 10(7):521\u2013526","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"6437_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1214::AID-CNCR22>3.0.CO;2-7","volume":"83","author":"K Mystakidou","year":"1998","unstructured":"Mystakidou K, Befon S, Liossi C, Vlachos L (1998) Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 83(6):1214\u20131223","journal-title":"Cancer."},{"issue":"3","key":"6437_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0885-3924(97)00349-7","volume":"15","author":"K Mystakidou","year":"1998","unstructured":"Mystakidou K, Befon S, Liossi C, Vlachos L (1998) Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manag 15(3):176\u2013184","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"6437_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2-5-319","volume":"2","author":"K Mystakidou","year":"1997","unstructured":"Mystakidou K, Befon S, Trifyllis J, Liossi C, Papadimitriou J (1997) Tropisetron versus metoclopramide in the control of emesis in far-advanced cancer. Oncologist. 2(5):319\u2013323","journal-title":"Oncologist."},{"issue":"2","key":"6437_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0885-3924(01)00323-2","volume":"22","author":"P Critchley","year":"2001","unstructured":"Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Bms, Latimer E, Jadad AR (2001) Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manag 22(2):631\u2013634","journal-title":"J Pain Symptom Manag"},{"issue":"9","key":"6437_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00520-004-0768-1","volume":"13","author":"A Kennett","year":"2005","unstructured":"Kennett A, Hardy J, Shah S, A\u2019Hern R (2005) An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer 13(9):715\u2013721","journal-title":"Support Care Cancer"},{"issue":"2","key":"6437_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/082585970402000209","volume":"20","author":"B Amesbury","year":"2004","unstructured":"Amesbury B, Alloway L, Hickmore E, Dewhurst G (2004) High-dose levomepromazine (methotrimeprazine) to control nausea in carcinoid syndrome. J Palliat Care 20(2):117\u2013118","journal-title":"J Palliat Care"},{"issue":"1","key":"6437_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1191\/0269216305pm972oa","volume":"19","author":"JH Eisenchlas","year":"2005","unstructured":"Eisenchlas JH, Garrigue N, Junin M, De Simone GG (2005) Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med 19(1):71\u201375","journal-title":"Palliat Med"},{"issue":"6","key":"6437_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23(6):526\u2013532","journal-title":"J Pain Symptom Manag"},{"issue":"8","key":"6437_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.12968\/hosp.1999.60.8.1176","volume":"60","author":"J Skinner","year":"1999","unstructured":"Skinner J, Skinner A (1999) Levomepromazine for nausea and vomiting in advanced cancer. Hosp Med 60(8):568\u2013570","journal-title":"Hosp Med"},{"issue":"20","key":"6437_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJM195411112512007","volume":"251","author":"F Homburger","year":"1954","unstructured":"Homburger F, Smithy G (1954) Chlorpromazine in patients with nausea and vomiting due to advanced cancer. N Engl J Med 251(20):820\u2013822","journal-title":"N Engl J Med"},{"issue":"5","key":"6437_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0016-5085(55)80084-4","volume":"28","author":"S Fink","year":"1955","unstructured":"Fink S, Winslow WA (1955) Anti-emetic effect of chlorpromazine (thorazine) in cancer patients. Gastroenterology. 28(5):731\u2013735","journal-title":"Gastroenterology."},{"issue":"1","key":"6437_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJM195701032560107","volume":"256","author":"F Homburger","year":"1957","unstructured":"Homburger F, Smithy G (1957) Proclorperazine for the treatment of nausea and vomiting in patients with advanced cancer and other chronic diseases. N Engl J Med 256(1):27","journal-title":"N Engl J Med"},{"issue":"5","key":"6437_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jpainsymman.2014.02.010","volume":"48","author":"DS Fletcher","year":"2014","unstructured":"Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ (2014) A randomized trial of the effectiveness of topical \u201cABH Gel\u201d (Ativan((R)), Benadryl((R)), Haldol((R))) vs. placebo in cancer patients with nausea. J Pain Symptom Manag 48(5):797\u2013803","journal-title":"J Pain Symptom Manag"},{"issue":"9","key":"6437_CR21","doi-asserted-by":"publisher","first-page":"e029942","DOI":"10.1136\/bmjopen-2019-029942","volume":"9","author":"JR Hardy","year":"2019","unstructured":"Hardy JR, Skerman H, Philip J, Good P, Currow DC, Mitchell G, Yates P (2019) Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial. BMJ Open 9(9):e029942","journal-title":"BMJ Open"},{"issue":"1","key":"6437_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpainsymman.2009.11.321","volume":"40","author":"JR Hardy","year":"2010","unstructured":"Hardy JR, O\u2019Shea A, White C, Gilshenan K, Welch L, Douglas C (2010) The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manag 40(1):111\u2013116","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"6437_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG et al (2020) Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial. JAMA Oncol 6(6):895\u2013899","journal-title":"JAMA Oncol"},{"key":"6437_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpainsymman.2020.12.023","volume":"62","author":"D Hui","year":"2021","unstructured":"Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E (2021) Fixed-dose netupitant and palonosetron for chronic nausea in cancer patients: a double-blind, placebo run-in pilot randomized clinical trial. J Pain Symptom Manag 62:223\u2013232.e1","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"6437_CR25","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/cam4.2091","volume":"8","author":"L Schwartzberg","year":"2019","unstructured":"Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V (2019) Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: efficacy data from 2 randomized, double-blind phase III studies. Cancer Med 8(5):2064\u20132073","journal-title":"Cancer Med"},{"issue":"1","key":"6437_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgo.2016.09.002","volume":"8","author":"M Aapro","year":"2017","unstructured":"Aapro M, Jordan K, Gralla RJ, Rizzi G, Rossi G, Palmas M, Alyasova AV, Lisyanskaya AS, Bo\u0161njak SM, Hesketh PJ (2017) Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. J Geriatr Oncol 8(1):56\u201363","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"6437_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00520-016-3502-x","volume":"25","author":"M Aapro","year":"2017","unstructured":"Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H (2017) NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer 25(4):1127\u20131135","journal-title":"Support Care Cancer"},{"issue":"4","key":"6437_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00520-019-4640-8","volume":"27","author":"S Baron-Hay","year":"2019","unstructured":"Baron-Hay S, Aapro M, Bernareggi A, Schwartzberg L (2019) Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 27(4):1309\u20131317","journal-title":"Support Care Cancer"},{"issue":"1","key":"6437_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jcph.198","volume":"54","author":"T Spinelli","year":"2014","unstructured":"Spinelli T, Calcagnile S, Giuliano C, Rossi G, Lanzarotti C, Mair S, Stevens L, Nisbet I (2014) Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 54(1):97\u2013108","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"6437_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/jpm.2018.0260","volume":"22","author":"TA Sande","year":"2019","unstructured":"Sande TA, Laird BJA, Fallon MT (2019) The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med 22(1):90\u201397","journal-title":"J Palliat Med"},{"issue":"7","key":"6437_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/0885-3924(91)90041-2","volume":"6","author":"E Campora","year":"1991","unstructured":"Campora E, Merlini L, Pace M, Bruzzone M, Luzzani M, Gottlieb A, Rosso R (1991) The incidence of narcotic-induced emesis. J Pain Symptom Manag 6(7):428\u2013430","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"6437_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2165\/00002018-199207030-00005","volume":"7","author":"SA Schug","year":"1992","unstructured":"Schug SA, Zech D, Grond S (1992) Adverse effects of systemic opioid analgesics. Drug Saf 7(3):200\u2013213","journal-title":"Drug Saf"},{"issue":"3","key":"6437_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1049909106289068","volume":"23","author":"P Glare","year":"2006","unstructured":"Glare P, Walsh D, Sheehan D (2006) The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 23(3):229\u2013235","journal-title":"Am J Hosp Palliat Care"},{"issue":"11","key":"6437_CR34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/2327-6924.12532","volume":"29","author":"T Mallick-Searle","year":"2017","unstructured":"Mallick-Searle T, Fillman M (2017) The pathophysiology, incidence, impact, and treatment of opioid-induced nausea and vomiting. J Am Assoc Nurse Pract 29(11):704\u2013710","journal-title":"J Am Assoc Nurse Pract"},{"issue":"3","key":"6437_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1634\/theoncologist.2017-0225","volume":"23","author":"H Tsukuura","year":"2018","unstructured":"Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, Gyawali B, Kubo Y, Ando M, Kondo M, Yamada K, Hasegawa Y, Ando Y (2018) Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (POINT): a randomized, placebo-controlled, double-blind trial. Oncologist. 23(3):367\u2013374","journal-title":"Oncologist."},{"issue":"3","key":"6437_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00520-001-0332-1","volume":"10","author":"J Hardy","year":"2002","unstructured":"Hardy J, Daly S, McQuade B, Albertsson M, Chimontsi-Kypriou V, Stathopoulos G, Curtis P (2002) A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 10(3):231\u2013236","journal-title":"Support Care Cancer"},{"issue":"1","key":"6437_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-018-4404-8","volume":"18","author":"J Hardy","year":"2018","unstructured":"Hardy J, Skerman H, Glare P, Philip J, Hudson P, Mitchell G, Martin P, Spruyt O, Currow D, Yates P (2018) A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer 18(1):510","journal-title":"BMC Cancer"},{"issue":"5","key":"6437_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","volume":"49","author":"DC Currow","year":"2015","unstructured":"Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag 49(5):814\u2013821","journal-title":"J Pain Symptom Manag"},{"key":"6437_CR39","first-page":"CD001219","volume":"2","author":"DJ Feuer","year":"2000","unstructured":"Feuer DJ, Broadley KE (2000) Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2:CD001219","journal-title":"Cochrane Database Syst Rev"},{"issue":"10055","key":"6437_CR40","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"P Mulvenna","year":"2016","unstructured":"Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, Morgan S, Lee C, Waite K, Bayman N, Pugh C, Sydes B, Stephens R, Parmar MK, Langley RE (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 388(10055):2004\u20132014","journal-title":"Lancet."}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06437-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06437-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06437-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T12:47:04Z","timestamp":1635252424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06437-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6437"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06437-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"NA","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David Hui grant from Helsinn.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}